Identifying protective dengue vaccines: guide to mastering an empirical process (Q38125045)

29 August 2017

Identifying protective dengue vaccines: guide to mastering an empirical process (English)

1 reference

29 August 2017

0 references

0 references

1

Scott B Halstead

1 reference

PubMed ID

23896423

29 August 2017

language of work or name

English

0 references

publication date

26 July 2013

1 reference

29 August 2017

1 reference

29 August 2017

31

1 reference

29 August 2017

41

1 reference

29 August 2017

4501-4507

1 reference

Vaccines for the prevention of dengue: development update

29 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.06.079

Next-generation dengue vaccines: novel strategies currently under development

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.06.079

From research to phase III: preclinical, industrial and clinical development of the Sanofi Pasteur tetravalent dengue vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.06.079

Next generation dengue vaccines: a review of candidates in preclinical development

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.06.079

The development of recombinant subunit envelope-based vaccines to protect against dengue virus induced disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.06.079

Development of DENVax: a chimeric dengue-2 PDK-53-based tetravalent vaccine for protection against dengue fever

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.06.079

A single dose of any of four different live attenuated tetravalent dengue vaccines is safe and immunogenic in flavivirus-naive adults: a randomized, double-blind clinical trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.06.079

Safety and immunogenicity of a tetravalent live-attenuated dengue vaccine in flavivirus naive children.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.06.079

Protective efficacy of the recombinant, live-attenuated, CYD tetravalent dengue vaccine in Thai schoolchildren: a randomised, controlled phase 2b trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.06.079

Dengue vaccine development: a 75% solution?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.06.079

A Protective Role for Dengue Virus-Specific CD8+ T Cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.06.079

Further Experiments in the Etiology of Dengue Fever

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.06.079

PRODUCTION OF IMMUNITY TO DENGUE WITH VIRUS MODIFIED BY PROPAGATION IN MICE.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.06.079

Research on dengue during World War II

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.06.079

Dengue 2 PDK-53 Virus as a Chimeric Carrier for Tetravalent Dengue Vaccine Development

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.06.079

Monoclonal antibody mapping of the envelope glycoprotein of the dengue 2 virus, Jamaica

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.06.079

An evaluation of dengue type-2 inactivated, recombinant subunit, and live-attenuated vaccine candidates in the rhesus macaque model

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.06.079

A single dose of the DENV-1 candidate vaccine rDEN1Δ30 is strongly immunogenic and induces resistance to a second dose in a randomized trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.06.079

Impact of infection or vaccination on pre-existing serological memory

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.06.079

Identification of human neutralizing antibodies that bind to complex epitopes on dengue virions

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.06.079

The structural basis for serotype-specific neutralization of dengue virus by a human antibody

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.06.079

Failure of secondary infection with American genotype dengue 2 to cause dengue haemorrhagic fever

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.06.079

Effect of dengue-1 antibodies on American dengue-2 viral infection and dengue haemorrhagic fever

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.06.079

Cross-serotype neutralization of dengue virus in Aotus nancymae monkeys

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.06.079

Enhanced severity of secondary dengue-2 infections: death rates in 1981 and 1997 Cuban outbreaks

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.06.079

Neutralizing antibodies after infection with dengue 1 virus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.06.079

Antibodies play a greater role than immune cells in heterologous protection against secondary dengue virus infection in a mouse model

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.06.079

A mouse model for studying dengue virus pathogenesis and immune response

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.06.079

Protection from secondary dengue virus infection in a mouse model reveals the role of serotype cross-reactive B and T cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.06.079

Insights into HLA-restricted T cell responses in a novel mouse model of dengue virus infection point toward new implications for vaccine design

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.06.079

Comprehensive analysis of dengue virus-specific responses supports an HLA-linked protective role for CD8+ T cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.06.079

Efficacy of tetravalent dengue vaccine in Thai schoolchildren

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.06.079

Analysis of repeat hospital admissions for dengue to estimate the frequency of third or fourth dengue infections resulting in admissions and dengue hemorrhagic fever, and serotype sequences.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.06.079

Dominant cross-reactive B cell response during secondary acute dengue virus infection in humans

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.06.079

Evaluation of interferences between dengue vaccine serotypes in a monkey model.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.06.079

Immunogenicity and safety of two live-attenuated tetravalent dengue vaccine formulations in healthy Australian adults.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.06.079

Phase 2 clinical trial of three formulations of tetravalent live-attenuated dengue vaccine in flavivirus-naïve adults

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.06.079

Interference and facilitation between dengue serotypes in a tetravalent live dengue virus vaccine candidate

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.06.079

Efficacy of a tetravalent chimeric dengue vaccine (DENVax) in Cynomolgus macaques

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.06.079

Viremia and immunogenicity in nonhuman primates of a tetravalent yellow fever-dengue chimeric vaccine: genetic reconstructions, dose adjustment, and antibody responses against wild-type dengue virus isolates

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.06.079

Safety and efficacy of chimeric yellow Fever-dengue virus tetravalent vaccine formulations in nonhuman primates

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.06.079

A novel tetravalent dengue vaccine is well tolerated and immunogenic against all 4 serotypes in flavivirus-naive adults

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.06.079

Recombinant chimeric yellow fever-dengue type 2 virus is immunogenic and protective in nonhuman primates

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.06.079

Live attenuated chimeric yellow fever dengue type 2 (ChimeriVax-DEN2) vaccine: Phase I clinical trial for safety and immunogenicity: effect of yellow fever pre-immunity in induction of cross neutralizing antibody responses to all 4 dengue serotypes.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.06.079

Relationship of preexisting dengue virus (DV) neutralizing antibody levels to viremia and severity of disease in a prospective cohort study of DV infection in Thailand

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.06.079

The dengue human challenge model: has the time come to accept this challenge?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.06.079

Experimental dengue virus challenge of human subjects previously vaccinated with live attenuated tetravalent dengue vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.06.079

Innate and adaptive cellular immunity in flavivirus-naïve human recipients of a live-attenuated dengue serotype 3 vaccine produced in Vero cells (VDV3).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.06.079

Safety and immunogenicity of a three dose regimen of two tetravalent live-attenuated dengue vaccines in five- to twelve-year-old Thai children

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.06.079

Systems biology approach predicts immunogenicity of the yellow fever vaccine in humans

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.06.079

Insights into human CD8(+) T-cell memory using the yellow fever and smallpox vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.06.079

CD4+ T cells are not required for the induction of dengue virus-specific CD8+ T cell or antibody responses but contribute to protection after vaccination

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.06.079

Effects of short-course oral corticosteroid therapy in early dengue infection in Vietnamese patients: a randomized, placebo-controlled trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.06.079

Dengue vascular permeability syndrome: what, no T cells?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.06.079

Vascular leakage in severe dengue virus infections: a potential role for the nonstructural viral protein NS1 and complement

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.06.079

Dengue virus nonstructural protein NS1 binds to prothrombin/thrombin and inhibits prothrombin activation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.06.079

Hemostatic changes in Vietnamese children with mild dengue correlate with the severity of vascular leakage rather than bleeding

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.06.079

Protection of mice against dengue 2 virus encephalitis by immunization with the dengue 2 virus non-structural glycoprotein NS1.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.06.079

The Fc portion of antibody to yellow fever virus NS1 is a determinant of protection against YF encephalitis in mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.06.079

Synergistic Interactions of Anti-NS1 Monoclonal Antibodies Protect Passively Immunized Mice from Lethal Challenge with Dengue 2 Virus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.06.079

Reduced risk of disease during postsecondary dengue virus infections

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.06.079

New mouse model for dengue virus vaccine testing

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.06.079

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/J.VACCINE.2013.06.079

1 reference

29 August 2017

1 reference

PubMed ID

23896423